Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. Dr. Schlesinger focuses on two abstracts concerning gout-related comorbidities, particularly cardiovascular disease. Dr. Mandell focus on two abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. Dr. Mandell also discuss 2 abstracts related to the systemic nature of gout; one abstract focuses on heart failure, while the other focuses on the lumbar spine. Finally, Dr. Mandell discuss the RECIPE trial recently published in 2021 that focuses on the use of immunomodulatory therapy to reduce the immunogenicity associated with pegloticase. So, on behalf of Dr. Schlesinger, I invite you to join us for this CME activity on research updates in gout.
1 AMA PRA Category 1 CreditTM
This activity was developed for rheumatologist, nephrologists, and other healthcare professionals involved in the care of patients with gout.
This activity is supported by an independent educational grant from Horizon Therapeutics.
Brian Mandell, MD, PhD
Professor and Chairman, Department of Academic Medicine
Rheumatology and Immunologic Disease
Naomi Schlesinger, MD
Professor of Medicine Chief, Division of Rheumatology
Rutgers-Robert Wood Johnson Medical School
New Brunswick, New Jersey